Additional analysis (PASS 1): training and validation, final models
| Variable | OR (95% CI) | p value |
|---|---|---|
| Training data set* | ||
| Age | 1.05 (1.02–1.09) | 0.004 |
| PASS 1 | 0.28 (0.12–0.66) | 0.004 |
| SF-12 PCS | 0.95 (0.91–0.98) | 0.003 |
| Willingness | 4.60 (1.70–12.50) | 0.003 |
| Tried injections | 1.64 (0.84–3.20) | 0.15 |
| Validation data set† | ||
| Age | 1.02 (0.99–1.06) | 0.20 |
| BMI | 1.06 (1.00–1.11) | 0.035 |
| Bilateral/unilateral symptoms | 0.49 (0.25–0.95) | 0.034 |
| PASS 1 | 0.22 (0.10–0.48) | < 0.001 |
| Willingness | 11.51 (3.57–37.07) | < 0.001 |
| Tried injections | 1.67 (0.86–3.22) | 0.13 |
| Allied health | 0.38 (0.12–1.22) | 0.10 |
BMI = body mass index; CI = confidence interval; OR = odds ratio; SF-12 PCS = Short-Form 12-item survey Physical Composite Scale.
↵* −2Logl = 218.833; Hosmer–Lemeshow χ28df = 7.30, p = 0.51. Final training model following 5 deletions.
↵† −2Logl = 215.370; Hosmer–Lemeshow χ28df = 1.04, p = 0.99. Final validation model following 3 deletions.